Search Cancer Clinical Trials

The Cancer Center offers patients access to a wide variety of clinical trials of promising new therapies. Use the search tool to find open protocols for your type of cancer.
28 results
  • Kidney Cancer, Lymphoma, Lung Cancer, Bladder Cancer, Melanoma

21-481          Phase I

A First-in-Human, Multicenter, Open-Label, Phase 1 Dose-Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TAB004 as Monotherapy and in Combination with Toripalimab in Subjects with Advanced Solid Malignancies including Lymphoma (View details on clinicaltrial.gov)

  • Melanoma, Head and Neck Cancer, Lymphoma, Lung Cancer

21-258          Phase II

A Multicenter Phase 1-2A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of LNS8801 in Patients With Advanced Cancer With and Without Pembrolizumab (View details on clinicaltrial.gov)

  • Lymphoma, Breast Cancer, Metastatic/Advanced Cancer, Sarcoma, Head and Neck Cancer, Ovarian Cancer, Leukemia

20-035          Phase II

A Multi-Center, Open Label Phase 1/2 Study of CYT-0851, an Oral RAD51 Inhibitor, in Patients With Relapsed/Refractory B-Cell Malignancies and Advanced Solid Tumors (View details on clinicaltrial.gov)

  • Lymphoma

21-595          Phase I

A Phase 1 Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies (View details on clinicaltrial.gov)

  • Lymphoma, Cellular Therapy

20-001          Phase I

A Phase 1, Multicenter, Open-Label Study of CC-97540, CD19-Targeted NEX-T Chimeric Antigen Receptor (CAR) T Cells, in Subjects with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (View details on clinicaltrial.gov)

  • Lymphoma, Cellular Therapy

15-404          Phase I

A Phase 1, Multicenter, Open-Label Study of JCAR017, CD19-targeted Chimeric Antigen Receptor (CAR) T Cells, for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) (View details on clinicaltrial.gov)

  • Lymphoma, Hodgkin's Disease

19-113          Phase II

A Phase 2 Front-Line PET/CT-2 Response-Adapted Brentuximab Vedotin and Nivolumab Incorporated and Radiation-Free Management of Early Stage Classical Hodgkin Lymphoma (cHL) (View details on clinicaltrial.gov)

  • Lymphoma

19-743          Phase II

A Phase 2 Study of MRD Adapted Therapy with Venetoclax-Obinutuzumab in Patients with High or Intermediate Risk Relapsed or Refractory CLL, with Addition of Acalabrutinib in Patients who Fail to Achieve MRD Eradication (View details on clinicaltrial.gov)

Showing 1 - 10 of 28 results